The discovery of a potent orally efficacious indole androgen receptor antagonist through in vivo screening
摘要:
A series of novel 2-(1H-indol-2-yl)-propan-2-ols have been designed, synthesized, and screened for their ability to inhibit testosterone-induced prostate weight increases in immature rats. Through the use of this paradigm, we were able to identify compounds that exhibited in vivo potency equal to that of the marketed antiandrogen Casodex (R) when orally administered. (c) 2006 Elsevier Ltd. All rights reserved.
Novel indole derivatives as selective androgen receptor modulator (SARMS)
申请人:Lanter C. James
公开号:US20050250740A1
公开(公告)日:2005-11-10
The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
本发明涉及新型吲哚衍生物,含有它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的应用。
NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)
申请人:Lanter James C.
公开号:US20090216023A1
公开(公告)日:2009-08-27
The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
本发明涉及新型吲哚衍生物,包含它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的应用。
Indole derivatives as selective androgen receptor modulators (sarms)
申请人:Janssen Pharmaceutica N.V.
公开号:EP2078712A1
公开(公告)日:2009-07-15
The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
MEDICINAL COMPOSITION FOR INHIBITING AMYLOID- PROTEIN DEPOSITION
申请人:Sumitomo Chemical Company, Limited
公开号:EP2246334A1
公开(公告)日:2010-11-03
The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound of the formula (I) or a pharmaceutically acceptable salt thereof to a mammal which may be diagnosed with an amyloid-β protein-related disease; and so on.